Bristol Myers Squibb (CELG-RI) Receivables - Net (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Receivables - Net of $10.6 billion for Q2 2026, down 7.55% year-over-year from $11.4 billion in Q2 2025, and up 12.65% quarter-over-quarter from $9.4 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Receivables - Net (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Receivables - Net for 18 consecutive years, with $10.6 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables - Net fell 7.55% year-over-year to $10.6 billion; the TTM figure through Jun 2026 stood at $10.6 billion (down 7.55% YoY), while the FY2025 annual figure was $11.4 billion, up 6.21% from the prior year.
- Receivables - Net advanced to $10.6 billion in Q2 2026 per CELG-RI's latest filing, from $9.4 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $11.4 billion in Q2 2024 and bottomed at $8.5 billion in Q1 2022.
- Historically, Receivables - Net has averaged $10.4 billion across 5 years, with a median of $10.5 billion in 2024.
- Annual changes were most pronounced in 2023 — Receivables - Net rose 18.13% — and 2026, when it dropped 13.27%.
- Bristol Myers Squibb's Receivables - Net stood at $9.9 billion in 2022, then gained by 10.47% to $10.9 billion in 2023, then dropped by 1.59% to $10.7 billion in 2024, then grew by 6.21% to $11.4 billion in 2025, then decreased by 7.54% to $10.6 billion in 2026.
- Business Quant data shows CELG-RI's Receivables - Net at $10.6 billion in Q2 2026, $9.4 billion in Q1 2026, and $11.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.55 Bn |
| Jun 30, 2026 | 10.55 Bn |
| Mar 31, 2026 | 9.37 Bn |
| Mar 31, 2026 | 9.37 Bn |
| Dec 31, 2025 | 11.41 Bn |
| Dec 31, 2025 | 11.41 Bn |
| Sep 30, 2025 | 11.42 Bn |
| Sep 30, 2025 | 11.42 Bn |
| Jun 30, 2025 | 11.42 Bn |
| Jun 30, 2025 | 11.42 Bn |
| Mar 31, 2025 | 10.80 Bn |
| Mar 31, 2025 | 10.80 Bn |
| Dec 31, 2024 | 10.75 Bn |
| Dec 31, 2024 | 10.75 Bn |
| Sep 30, 2024 | 11.03 Bn |
| Sep 30, 2024 | 11.03 Bn |
| Jun 30, 2024 | 11.42 Bn |
| Jun 30, 2024 | 11.42 Bn |
| Mar 31, 2024 | 10.45 Bn |
| Mar 31, 2024 | 10.45 Bn |